Valuation: Nuvectis Pharma, Inc.

Market Cap 653M 583M 539M 488M 914M 62.01B 929M 6.49B 2.57B 32.49B 2.45B 2.4B 102B P/E 2026 *
-19.2x
P/E 2027 * -17.4x
Enterprise Value 653M 583M 539M 488M 914M 62.01B 929M 6.49B 2.57B 32.49B 2.45B 2.4B 102B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
65.57%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Nuvectis Pharma, Inc.

1 day-4.02%
1 week+7.80%
Current month-5.07%
1 month-4.84%
3 months-0.50%
6 months+128.10%
Current year+165.56%
1 week 17.85
Extreme 17.85
21.72
1 month 17.68
Extreme 17.68
22.24
Current year 7.17
Extreme 7.17
29.28
1 year 5.55
Extreme 5.55
29.28
3 years 4.44
Extreme 4.44
29.28
5 years 3.08
Extreme 3.08
29.28
10 years 3.08
Extreme 3.08
29.28
Manager TitleAgeSince
Chief Operating Officer 43 2020-07-26
Chief Executive Officer 60 2020-07-26
Chief Tech/Sci/R&D Officer 60 2020-07-26
Director TitleAgeSince
Director/Board Member 61 2021-06-30
Director/Board Member 50 2021-06-30
Director/Board Member 58 2021-08-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/3/26 Free

Chief Financial Officer

30,000 0.0952%
6/30/26 Buy 50,000 0.1885%
6/30/26 Buy

Chief Executive Officer

12,500 0.0471%
Change 5-day change 1-year change 3-year change Capi.($)
-4.02%+7.80%+233.61%+122.78% 653M
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average -0.15%+2.95%+67.92%+154.07% 38.38B
Weighted average by Cap. +0.38%+2.74%+47.89%+158.51%

Financials

2026 *2027 *
Net sales - -
Net income -27.97M -24.98M -23.08M -20.91M -39.12M -2.66B -39.77M -278M -110M -1.39B -105M -103M -4.39B -34.61M -30.91M -28.55M -25.87M -48.41M -3.29B -49.21M -344M -136M -1.72B -130M -127M -5.43B
Net Debt - -
Projected Income Statement - Annual - Nuvectis Pharma, Inc.
Logo Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is developing two drug candidates: NXP800 and NXP900. NXP800 is a small molecule GCN2 activator that has been evaluated in a Phase Ib clinical trial for the treatment of platinum-resistant, ARID1a-mutated ovarian cancer, and it is exploring other development opportunities for NXP800. Chronic activation of GCN2 by NXP800 leads to cancer cell death. NXP900 is a targeted-therapy, small molecule drug candidate that inhibits the proto-oncogene c-Src (SRC) and YES1 kinases, which is in the Phase Ib program. SRC is aberrantly activated in many cancer types, including solid tumor cancers such as breast, colon, prostate, pancreatic and ovarian cancers. YES1 is a nonreceptor tyrosine kinase that belongs to the SRC family of kinases and controls multiple cancer signaling pathways.
Employees
16
Date Price Change Volume
26-10-23 US$20.05 -4.02% 107,946
26-10-22 US$20.89 +0.92% 110,052
26-10-21 US$20.70 +0.53% 203,582
26-10-20 US$20.59 +8.71% 148,773
26-10-19 US$18.94 +1.83% 198,177
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Nuvectis Pharma, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
20.05USD
Average target price
35.40USD
Spread / Average Target
+76.56%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Nuvectis Pharma, Inc.
  1. Stock Market
  2. Stocks
  3. NVCT Stock